About Us

Milestones|

2017
  • 2017-07
  • LZM009 got US FDA IND apparoval.
  • 2016-11
  • LZM002C and LZM005 were approved for phase I clinical trials.

    AT132 was approved for phase II/III clinical trials.

    2016
    2016
  • 2016-09
  • LZM003 is approved for clinical trials.

  • 2016-01
  • Invested in Abcyte initiating its strategic transformation into the field of multifunctional antibody.

    2016
    2014
  • 2014-09
  •  Newly-built R&D center was officially put into use.

  • 2014-02
  • AT132 is approved for clinical trials.

    2014
    2013
  • 2013-08
  • Introduced “The third batch of Chinese and overseas Chinese entrepreneurial team propped up by the State Council” which was headed by Dr. Daotian Fu.

  • 2012-04
  • Submit AT132 clinical trial application to CFDA.

    2012
    2010
  • 2010-07
  • Established in 2010 with 533 million yuan registered capital.